Human dendritic cells efficiently phagocytose adenoviral oncolysate but require additional stimulation to mature

International Journal of Cancer

Volumn 130, Issue 7, 2012, Pages 1682-1694

  Schierer, Stephan ^a   Hesse, Andrea ^a   Knippertz, Ilka ^a   Kaempgen, Eckhart ^a   Baur, Andreas S ^a   Schuler, Gerold ^a   Steinkasserer, Alexander ^a   Nettelbeck, Dirk M ^a,b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

DC maturation; dendritic cell; oncolytic adenovirus; tumor vaccination; virotherapy

Indexed keywords

CD40 LIGAND; VIRUS ONCOLYSATE;

ADENOVIRUS; ADENOVIRUS INFECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CELL DEATH; CELL MATURATION; CELL PHAGOCYTOSIS; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE GENE; IMMUNOSTIMULATION; LYMPHOCYTE MIGRATION; MELANOMA CELL; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME;

ADENOVIRIDAE; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; CELL DEATH; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINE CCL19; DENDRITIC CELLS; HEK293 CELLS; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; NECROSIS; ONCOLYTIC VIRUSES; PEPTIDES; PHAGOCYTOSIS; TUMOR CELLS, CULTURED;

EID: 84856325607     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26176     Document Type: Article

References (50)

1. Parato KA, Senger D, Forsyth PAJ, Bell JC,. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005; 5: 965-76. (Pubitemid 41766784)
2. Toda M, Rabkin SD, Kojima H, Martuza RL,. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999; 10: 385-93. (Pubitemid 29097317)
3. Miller CG, Fraser NW,. Role of the immune response during neuro-attenuated herpes simplex virus-mediated tumor destruction in a murine intracranial melanoma model. Cancer Res 2000; 60: 5714-22.
4. Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, Thompson J, Valdes M, Barber G, Vile RG,. Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 2007; 67: 2840-8. (Pubitemid 46548974)
5. Yamamoto M, Curiel DT,. Current issues and future directions of oncolytic adenoviruses. Mol Ther 2010; 18: 243-50.
6. Liu TC, Kirn D,. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res 2007; 67: 429-32. (Pubitemid 46192175)
7. Cody JJ, Douglas JT,. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 2009; 16: 473-88.
8. Shayakhmetov DM, Li ZY, Ni S, Lieber A,. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res 2002; 62: 1063-8. (Pubitemid 34160288)
9. Li ZY, Ni S, Yang X, Kiviat N, Lieber A,. Xenograft models for liver metastasis: relationship between tumor morphology and adenovirus vector transduction. Mol Ther 2004; 9: 650-7. (Pubitemid 38660417)
10. Hallden G, Hill R, Wang Y, Anand A, Liu TC, Lemoine NR, Francis J, Hawkins L, Kirn D,. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther 2003; 8: 412-24. (Pubitemid 37161463)
11. Bernt KM, Ni S, Tieu AT, Lieber A,. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res 2005; 65: 4343-52. (Pubitemid 40775673)
12. Lee YS, Kim JH, Choi KJ, Choi IK, Kim H, Cho S, Cho BC, Yun CO,. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res 2006; 12: 5859-68. (Pubitemid 44629619)
13. Ramakrishna E, Woller N, Mundt B, Knocke S, Gurlevik E, Saborowski M, Malek N, Manns MP, Wirth T, Kuhnel F, Kubicka S,. Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res 2009; 69: 1448-58.
14. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, Wold WS,. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270-6. (Pubitemid 43259903)
15. Steinman RM, Hemmi H,. Dendritic cells: translating innate to adaptive immunity. Curr Topics Microbiol Immunol 2006; 311: 17-58. (Pubitemid 47413194)
16. Palucka AK, Ueno H, Fay J, Banchereau J,. Dendritic cells: a critical player in cancer therapy? J. Immunother 2008; 31: 793-805.
17. Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT,. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 2002; 62: 4663-70.
18. Banerjee NS, Rivera AA, Wang M, Chow LT, Broker TR, Curiel DT, Nettelbeck DM,. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A. E4, or both in submerged cells and organotypic cultures. Mol Cancer Ther 2004; 3: 437-49. (Pubitemid 39193721)
19. Rivera AA, Davydova J, Schierer S, Wang M, Krasnykh V, Yamamoto M, Curiel DT, Nettelbeck DM,. Combining high selectivity of replication with fiber chimerism for effective adenoviral oncolysis of CAR-negative melanoma cells. Gene Ther 2004; 11: 1694-702. (Pubitemid 39591764)
20. Schierer S, Hesse A, Muller I, Kampgen E, Curiel DT, Schuler G, Steinkasserer A, Nettelbeck DM,. Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses. Int J Cancer 2008; 122: 219-29. (Pubitemid 350209999)
21. Engelmayer J, Larsson M, Subklewe M, Chahroudi A, Cox WI, Steinman RM, Bhardwaj N,. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol 1999; 163: 6762-8.
22. Mikloska Z, Bosnjak L, Cunningham AL,. Immature monocyte-derived dendritic cells are productively infected with herpes simplex virus type 1. J Virol 2001; 75: 5958-64. (Pubitemid 32553126)
23. Humrich JY, Thumann P, Greiner S, Humrich JH, Averbeck M, Schwank C, Kampgen E, Schuler G, Jenne L,. Vaccinia virus impairs directional migration and chemokine receptor switch of human dendritic cells. Eur J Immunol 2007; 37: 954-65. (Pubitemid 46925333)
24. Kummer M, Turza NM, Muhl-Zurbes P, Lechmann M, Boutell C, Coffin RS, Everett RD, Steinkasserer A, Prechtel AT,. Herpes simplex virus type 1 (HSV-1) induces CD83 degradation in mature dendritic cells with immediate early kinetics via the cellular proteasome. J Virol 2007; 81: 6326-38. (Pubitemid 46878039)
25. Prestwich RJ, Errington F, Ilett EJ, Morgan RS, Scott KJ, Kottke T, Thompson J, Morrison EE, Harrington KJ, Pandha HS, Selby PJ, Vile RG, et al. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res 2008; 14: 7358-66.
26. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S,. Antigen presentation and T cell stimulation by dendritic cells. Ann Review Immunol 2002; 20: 621-67. (Pubitemid 34293436)
27. Lanzavecchia A, Sallusto F,. Regulation of T cell immunity by dendritic cells. Cell 2001; 106: 263-6. (Pubitemid 32772609)
28. Takahashi S, Yotnda P, Rousseau RF, Mei Z, Smith S, Rill D, Younes A, Brenner MK,. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Cancer Gene Ther 2001; 8: 378-87. (Pubitemid 32685645)
29. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N,. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191: 423-34.
30. Kepp O, Tesniere A, Schlemmer F, Michaud M, Senovilla L, Zitvogel L, Kroemer G,. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009; 14: 364-75.
31. Brusa D, Migliore E, Garetto S, Simone M, Matera L,. Immunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells. Prostate 2009; 69: 1343-52.
32. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G,. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008; 15: 3-12. (Pubitemid 350286167)
33. Ma DY, Clark EA,. The role of CD40 and CD154/CD40L in dendritic cells. Sem Immunol 2009; 21: 265-72.
34. Abou El Hassan MA, van der Meulen-Muileman I, Abbas S, Kruyt FA,. Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death. J Virol 2004; 78: 12243-51. (Pubitemid 39458744)
35. Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR, McNeish IA,. Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene 2008; 27: 3081-90. (Pubitemid 351693172)
36. Endo Y, Sakai R, Ouchi M, Onimatsu H, Hioki M, Kagawa S, Uno F, Watanabe Y, Urata Y, Tanaka N, Fujiwara T,. Virus-mediated oncolysis induces danger signal and stimulates cytotoxic T-lymphocyte activity via proteasome activator upregulation. Oncogene 2008; 27: 2375-81. (Pubitemid 351521091)
37. Rohmer S, Quirin C, Hesse A, Sandmann S, Bayer W, Herold-Mende C, Haviv YS, Wildner O, Enk AH, Nettelbeck DM,. Transgene expression by oncolytic adenoviruses is modulated by E1B19K deletion in a cell type-dependent manner. Virology 2009; 395: 243-54.
38. Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Kondo S, McCormick F, Xu J, Kondo Y, Bekele BN, Colman H, Lang FF, Fueyo J,. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 2007; 99: 1410-4. (Pubitemid 351767180)
39. Pulendran B, Immune activation: death, danger and dendritic cells. Curr Biol 2004; 14: R30-R32. (Pubitemid 38069967)
40. Rohn TA, Schadendorf D, Sun Y, Nguyen XD, Roeder D, Langen H, Vogt AB, Kropshofer H,. Melanoma cell necrosis facilitates transfer of specific sets of antigens onto MHC class II molecules of dendritic cells. Eur J Immunol 2005; 35: 2826-39. (Pubitemid 41555079)
41. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G,. Immunological aspects of cancer chemotherapy. Nat Rev 2008; 8: 59-73.
42. Ciocca DR, Calderwood SK,. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones 2005; 10: 86-103. (Pubitemid 40942470)
43. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G,. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184: 747-52. (Pubitemid 26324129)
44. Mackey MF, Gunn JR, Maliszewsky C, Kikutani H, Noelle RJ, Barth RJ, Jr,. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 1998; 161: 2094-8. (Pubitemid 28397017)
45. Liu KJ, Lu LF, Cheng HT, Hung YM, Shiou SR, Whang-Peng J, Juang SH,. Concurrent delivery of tumor antigens and activation signals to dendritic cells by irradiated CD40 ligand-transfected tumor cells resulted in efficient activation of specific CD8+ T cells. Cancer Gene Ther 2004; 11: 135-47. (Pubitemid 38141776)
46. Moehler MH, Zeidler M, Wilsberg V, Cornelis JJ, Woelfel T, Rommelaere J, Galle PR, Heike M,. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum Gene Ther 2005; 16: 996-1005. (Pubitemid 41153868)
47. Greiner S, Humrich JY, Thuman P, Sauter B, Schuler G, Jenne L,. The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin Exp Immunol 2006; 146: 344-53. (Pubitemid 44581351)
48. Bai L, Koopmann J, Fiola C, Fournier P, Schirrmacher V,. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. Int J Oncol 2002; 21: 685-94.
49. Gauvrit A, Brandler S, Sapede-Peroz C, Boisgerault N, Tangy F, Gregoire M,. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. Cancer Res 2008; 68: 4882-92.
50. Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, Vile RG,. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 2009; 20: 1119-32.